101 
Biota - HRV Phase II trial underway in patients
Biota (ASX:BTA) today announced the commencement of a Phase II clinical trial of the antiviral drug BTA798 in patients with chronic asthma. BTA798 is orally administered and active against human rhinovirus, a virus often associated with the common cold. The US Food and Drug Administration (FDA) recently provided regula… Read all
|
A vaginal gel containing Gilead’s AIDS drug cut HIV infections - related to ASX Starpharma play?
A vaginal gel containing Gilead Sciences Inc.’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa. Among 445 women who applied the gel before and after sex, there were 39 percent fewer HIV infections overall than among those who used a placebo gel, according to the trial results released today by the journal Science. There were 54 percent fewer infections… Read all |
Preferred Bidders for Healthscope named
Private equity groups Carlyle Group and TPG Capital have won the bidding war for Healthscope Ltd, Australia's second largest private hospital operator, The Australian reports. The newspaper said it understood the final offer price was $6.26 a share, above early indicative offers of $5.80 per share. |
USA Venture Funding to Highest in 2 Years – a precursor to the Australia trend?
Venture capital funding in the second quarter jumped to the highest level in almost two years, as investors increased their bets on alternative energy and biotechnology. |
PwC report came out for the Australian Life Sciences sector Q4 2010
PricewaterhouseCoopers has released its BioForum report for the fourth quarter FY10 showing a fall of 9.5 per cent for the local Life Sciences Index, which performed slightly better than the broader market. To a degree the subsectors of biotech and medical devices balanced each other out.
|
ChemGenex and U.S. FDA Agree on Potential Regulatory Pathway for OMAPROTM
ChemGenex Pharmaceuticals Limited (ASX: CXS) announced today it has agreed with the U.S. Food and Drug Administration (FDA) a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML). The recent Type A Meeting, which included discussio… Read all
|
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use